The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

Medicine and Dentistry

• Development 100%
• Non Small Cell Lung Cancer 66%
• Therapy Resistance 66%
• Combination Therapy 33%
• Tumor Progression 33%
• Angiogenesis 33%
• Metastatic Carcinoma 33%
• Solid Malignant Neoplasm 33%
• Protein Tyrosine Kinase 33%
• Immunotherapy 33%
• Exercise 33%
• Mesenchymal-Epithelial Transition 33%
• Lung Cancer 33%
• Tyrosine-Kinase Inhibitor 33%
• Immunosuppressive Treatment 33%
• Monoclonal Antibody 33%
• Cancer Therapy 33%
• Antibody-Drug Conjugate 33%
• Thinking 33%
• Patient 33%
• Survival 33%
• Therapeutic Procedure 33%
• Inpatient 33%
• Marker 33%
• Family 33%
• Cancer Types 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Study 100%
• Non Small Cell Lung Cancer 66%
• Prognosis 66%
• Therapy Resistance 66%
• Protein Tyrosine Kinase 33%
• Protein Tyrosine Kinase Inhibitor 33%
• Metastasis 33%
• Tumor Growth 33%
• Immunotherapy 33%
• Solid Malignant Neoplasm 33%
• Lung Cancer 33%
• Monoclonal Antibody 33%
• Antibody Drug Conjugate 33%
• Preclinical Study 33%
• Survival 33%

Biochemistry, Genetics and Molecular Biology

• Development 100%
• Angiogenesis 33%
• Cell Growth 33%
• Receptor Tyrosine Kinase 33%
• Small Molecule 33%
• Solid 33%
• Monoclonal Antibody 33%
• Exercise 33%
• Mesenchymal-Epithelial Transition 33%
• Survival 33%
• thought 33%
• Conjugate 33%
• Antibody 33%